IGF1 and cancer: For instance, substantial decreases in IGF-1 and IGFBP-1 (both p = 0.11) and increases in NOS3 gene expression (p = 0.13), which would provide further evidence that eTRF may slow aging and reduce cancer risk, did not reach statistical significance.